Cite
Gallois C, Emile JF, Kim S, et al. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Dig Liver Dis. 2021;53(10):1254-1259doi: 10.1016/j.dld.2021.06.009.
Gallois, C., Emile, J. F., Kim, S., Monterymard, C., Gilabert, M., Bez, J., Lièvre, A., Dahan, L., Laurent-Puig, P., Mineur, L., Coriat, R., Legoux, J. L., Hautefeuille, V., Phelip, J. M., Lecomte, T., Sokol, H., Capron, C., Randrian, V., Lepage, C., Lomenie, N., Kurtz, C., Taieb, J., & Tougeron, D. (2021). Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(10), 1254-1259. https://doi.org/10.1016/j.dld.2021.06.009
Gallois, Claire, et al. "Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver vol. 53,10 (2021): 1254-1259. doi: https://doi.org/10.1016/j.dld.2021.06.009
Gallois C, Emile JF, Kim S, Monterymard C, Gilabert M, Bez J, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Coriat R, Legoux JL, Hautefeuille V, Phelip JM, Lecomte T, Sokol H, Capron C, Randrian V, Lepage C, Lomenie N, Kurtz C, Taieb J, Tougeron D. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Dig Liver Dis. 2021 Oct;53(10):1254-1259. doi: 10.1016/j.dld.2021.06.009. Epub 2021 Jun 30. PMID: 34215534.
Copy
Download .nbib